This afternoon we watched Verona Pharma drop -4.2% to a price of $90.59 per share. The Mid-Cap Pharmaceutical company is now trading -23.93% below its average target price of $119.09. Analysts have set target prices ranging from $90.0 to $170.0 per share for Verona Pharma, and have given the stock an average rating of buy.
The stock has an above average percentage of its shares sold short at 10.3%, and a short ratio of 6.19. Since 10.4% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 91.0% of Verona Pharma's shares being owned by this investor type.
Institutions Invested in Verona Pharma
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-03-31 | Perceptive Advisors Llc | 8% | 6,563,340 | $594,605,795 |
| 2025-03-31 | Janus Henderson Group PLC | 6% | 5,516,889 | $499,802,565 |
| 2025-03-31 | Darwin Global Management, Ltd. | 5% | 3,923,204 | $355,422,671 |
| 2025-03-31 | Frazier Life Sciences Management, L.P. | 4% | 3,457,850 | $313,263,924 |
| 2025-03-31 | Eventide Asset Management LLC | 3% | 2,893,437 | $262,130,928 |
| 2025-03-31 | RTW Investments LP | 3% | 2,848,800 | $258,087,039 |
| 2025-03-31 | NEA Management Company, LLC | 3% | 2,688,565 | $243,570,549 |
| 2025-03-31 | Summit Partners Public Asset Management LLC | 3% | 2,323,115 | $210,462,606 |
| 2025-03-31 | Wellington Management Group, LLP | 2% | 2,131,502 | $193,103,426 |
| 2025-03-31 | Price (T.Rowe) Associates Inc | 2% | 1,866,280 | $169,075,638 |
Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on Verona Pharma.
